[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anti-achr-antibody-positive\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anti-achr-antibody-positive":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100590443","early-ravulizumab-treatment-of-anti--achr-antibody-positive-generalized-myasthenia-gravis-100590443",false,"NCT06967480","Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis","MG-EVOLUTION. Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis: A Real-World Study With Biomarker Analysis","Inclusion Criteria:\n\n* Diagnosis of MG confirmed by:\n\n  * History of a positive serologic test for anti-AChR antibodies, and\n  * One of the following:\n\n    * History of abnormal neuromuscular transmission test demonstrated by singlefibre electromyography or repetitive nerve stimulation\n    * History of positive anticholinesterase test (e.g., edrophonium chloride test); or\n    * Patient demonstrated improvement in MG signs on oral cholinesterase inhibitors, as assessed by the treating physician\n* Disease duration from MG onset ≤ 3 years before T-4 (Enrolment);\n* MGFA class IIb to IV;\n* Patient eligible for Ravulizumab treatment based on AIFA reimbursement criteria\n* Vaccination cycle for Neisseria meningitidis completed at least two weeks before Ravulizumab initiation or antibiotics chemoprophylaxis according to the SmPC.\n\nExclusion Criteria:\n\n* Patient unable to understand and sign the informed consent\n* Hypersensitivity to the active substance or to any of the excipients of the study product\n* Patient for whom the study product is contraindicated according to SmPC\n* Previous treatment with C5 inhibitors\n* Last rituximab infusion performed \\\u003C 6 months before T-4 (Enrolment)\n* Last infusion with FcRn blockers performed \\\u003C 3 months before T-4 (Enrollment)\n* Pregnant or lactating or planning a pregnancy during the study\n* Patient who plan to relocate during the study\n* Patient who are unsure of following the visit schedule\n* Patient unable to complete questionnaires\n* Previous or current participation to other interventional studies","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","OBSERVATIONAL","The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.",[24,25],"Generalized Myasthenia Gravis","Anti-AChR Antibody Positive",[27,24,28,29],"Anti-AChR Antibody-Positive","gMG","Ravulizumab","RECRUITING","2026-02-04",{"date":33,"type":34},"2026-02-05","ACTUAL",{"date":36,"type":34},"2025-07-31",{"date":38,"type":20},"2027-06-30",{"name":40,"class":41},"Alexion Pharmaceuticals, Inc.","INDUSTRY",23]